CeNeRx BioPharma recently raised $15 million in a second round of funding contributed by Aisling Capital, L Capital Partners and Pappas Ventures. The Cary, N.C. company specializes in treatments for central nervous system disorders. It plans to use the money to push its lead drug candidate, Tyrima — intended for treatment of severe depression — through the second phase of clinical trials.
This is CeNeRx’s first round of funding since 2005, when it raised $18.5 million. It received an additional $2.5 million in venture debt from Oxford Finance in 2006, reports VentureWire. In addition to Tyrima, the company is working on several other compounds that could be used to treat pain, obesity and overactive bladder symptoms.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.
